Supernus Pharmaceuticals Stock Price, News & Analysis (NASDAQ:SUPN)

$39.40 +0.95 (+2.47 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$39.40
Today's Range$37.85 - $39.70
52-Week Range$24.92 - $50.04
Volume291,143 shs
Average Volume719,570 shs
Market Capitalization$2.07 billion
P/E Ratio35.82
Dividend YieldN/A
Beta1.08

About Supernus Pharmaceuticals (NASDAQ:SUPN)

Supernus Pharmaceuticals logoSupernus Pharmaceuticals, Inc. is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy. In addition, it is developing multiple product candidates in psychiatry to address unmet medical needs and market opportunities for the treatment of impulsive aggression (IA) and for the treatment of attention deficit hyperactivity disorder (ADHD). It is developing SPN-810 (molindone hydrochloride) to treat IA in patients having ADHD. It is developing SPN-812 (viloxazine hydrochloride) as a candidate to treat patients having ADHD. The Company's neurology portfolio consists of Oxtellar XR and Trokendi XR, which are the first once-daily extended release oxcarbazepine and topiramate products, respectively, indicated for epilepsy in the United States market.

Receive SUPN News and Ratings via Email

Sign-up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Specialty & Advanced Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorSpecialty & Advanced Pharmaceuticals
SymbolNASDAQ:SUPN
CUSIP86845910
Phone+1-301-8382500

Debt

Debt-to-Equity RatioN/A
Current Ratio1.82%
Quick Ratio1.68%

Price-To-Earnings

Trailing P/E Ratio35.8181818181818
Forward P/E Ratio36.82
P/E GrowthN/A

Sales & Book Value

Annual Sales$215 million
Price / Sales9.39
Cash Flow$1.09 per share
Price / Cash36.17
Book Value$3.83 per share
Price / Book10.29

Profitability

Trailing EPS$1.10
Net Income$91.22 million
Net Margins20.98%
Return on Equity26.37%
Return on Assets17.00%

Miscellaneous

Employees363
Outstanding Shares51,260,000

Supernus Pharmaceuticals (NASDAQ:SUPN) Frequently Asked Questions

What is Supernus Pharmaceuticals' stock symbol?

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

How were Supernus Pharmaceuticals' earnings last quarter?

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) posted its quarterly earnings results on Monday, November, 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.27 by $0.02. The specialty pharmaceutical company earned $80.40 million during the quarter, compared to analyst estimates of $78.74 million. Supernus Pharmaceuticals had a net margin of 20.98% and a return on equity of 26.37%. Supernus Pharmaceuticals's revenue was up 41.5% on a year-over-year basis. View Supernus Pharmaceuticals' Earnings History.

When will Supernus Pharmaceuticals make its next earnings announcement?

Supernus Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February, 27th 2018. View Earnings Estimates for Supernus Pharmaceuticals.

Where is Supernus Pharmaceuticals' stock going? Where will Supernus Pharmaceuticals' stock price be in 2018?

10 brokerages have issued 12-month price objectives for Supernus Pharmaceuticals' stock. Their forecasts range from $41.00 to $66.00. On average, they anticipate Supernus Pharmaceuticals' share price to reach $51.90 in the next year. View Analyst Ratings for Supernus Pharmaceuticals.

What are Wall Street analysts saying about Supernus Pharmaceuticals stock?

Here are some recent quotes from research analysts about Supernus Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. " (1/12/2018)
  • 2. FBR & Co analysts commented, "We are initiating coverage of Supernus Pharmaceuticals (SUPN) with a Buy rating and a 12-month price target of $53 per share. We see strong revenue growth exceeding 25% per year for 2017–2019 with in-line drugs Trokendi XR (epilepsy/ migraine) and Oxtellar XR (epilepsy) driving growth. Starting in 2020, we expect contribution from late-stage pipeline drugs SPN-812, which is a non-stimulant ADHD drug, and SPN-810 for impulsive aggression. We model EPS at $1.05 in 2017, $1.70 in 2018, and $2.35 in 2019 including a full tax rate. Our 2017 EPS estimate compares unfavorably to 2016, which included a tax benefit of $40.8 million or ~$0.80 per share. Our price target averages our DCF valuation and a P/E-derived target, which is 35x 2018E EPS of $1.70 discounted to present at 10%. At current prices, the shares have corrected by ~18% from all-time highs after an update on pipeline drug SPN-810 raised risks on timing/approvability. We see this drop as an opportunity to establish positions." (10/19/2017)
  • 3. Cantor Fitzgerald analysts commented, "Interim look at SPN-810 Phase 3 program leads to elimination of the low dose. SUPN announced that an interim analysis of the ongoing Phase 3 trials (CHIME 1 and CHIME 2) in impulsive aggression (IA) resulted in the decision to discontinue the low dose arm, 18mg daily, and randomization of future clinical trial subjects to receive either placebo or 36mg per day." (9/19/2017)
  • 4. Jefferies Group LLC analysts commented, "Following Monday's Zydus settlement, SUPN reached a similar agreement with TEVA on the Trokendi XR (TXR) patent challenge ' allowing generic entry starting January 2023. There is now much more certainty in SUPN's ability to maintain cash flows from 76% of its current epilepsy franchises at least through 2022 and another 24% through 2027 (OXR), bridging to the latestage pipeline, which should come online in 2020. Importantly, SUPN fits with our M&A thesis." (3/8/2017)

Who are some of Supernus Pharmaceuticals' key competitors?

Who are Supernus Pharmaceuticals' key executives?

Supernus Pharmaceuticals' management team includes the folowing people:

  • Charles W. Newhall III, Independent Chairman of the Board (Age 72)
  • Jack A. Khattar, President, Chief Executive Officer, Secretary, Director (Age 55)
  • Gregory S. Patrick Ph.D., Chief Financial Officer, Vice President (Age 65)
  • Stefan K. F. Schwabe M.D. Ph.D., Executive Vice-President - Research and Development, Chief Medical Officer (Age 65)
  • Padmanabh P. Bhatt Ph.D., Senior Vice President - Intellectual Property, Chief Scientific Officer (Age 59)
  • Victor Vaughn, Senior Vice President - Sales and Marketing (Age 59)
  • Georges Gemayel Ph.D., Independent Director (Age 56)
  • Frederick M. Hudson CPA, Independent Director (Age 71)
  • John M. Siebert Ph.D., Independent Director (Age 77)

Who owns Supernus Pharmaceuticals stock?

Supernus Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.47%), Bank of New York Mellon Corp (2.79%), Rice Hall James & Associates LLC (2.58%), Acadian Asset Management LLC (2.50%), Champlain Investment Partners LLC (2.37%) and Ashford Capital Management Inc. (1.47%). Company insiders that own Supernus Pharmaceuticals stock include Gregory S Patrick, Padmanabh P Bhatt, Stefan KF Schwabe and Victor Vaughn. View Institutional Ownership Trends for Supernus Pharmaceuticals.

Who sold Supernus Pharmaceuticals stock? Who is selling Supernus Pharmaceuticals stock?

Supernus Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Ranger Investment Management L.P., Deutsche Bank AG, Glenmede Trust Co. NA, Royce & Associates LP, Bank of New York Mellon Corp, TIAA CREF Investment Management LLC, Emerald Advisers Inc. PA and Goldman Sachs Group Inc.. Company insiders that have sold Supernus Pharmaceuticals company stock in the last year include Gregory S Patrick, Padmanabh P Bhatt, Stefan KF Schwabe and Victor Vaughn. View Insider Buying and Selling for Supernus Pharmaceuticals.

Who bought Supernus Pharmaceuticals stock? Who is buying Supernus Pharmaceuticals stock?

Supernus Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Stephens Investment Management Group LLC, Wells Fargo & Company MN, BlackRock Inc., Rice Hall James & Associates LLC, Capital Fund Management S.A., Cortina Asset Management LLC, Two Sigma Investments LP and William Blair Investment Management LLC. View Insider Buying and Selling for Supernus Pharmaceuticals.

How do I buy Supernus Pharmaceuticals stock?

Shares of Supernus Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Supernus Pharmaceuticals' stock price today?

One share of Supernus Pharmaceuticals stock can currently be purchased for approximately $39.40.

How big of a company is Supernus Pharmaceuticals?

Supernus Pharmaceuticals has a market capitalization of $2.07 billion and generates $215 million in revenue each year. The specialty pharmaceutical company earns $91.22 million in net income (profit) each year or $1.10 on an earnings per share basis. Supernus Pharmaceuticals employs 363 workers across the globe.

How can I contact Supernus Pharmaceuticals?

Supernus Pharmaceuticals' mailing address is 1550 E Gude Dr, ROCKVILLE, MD 20850-1339, United States. The specialty pharmaceutical company can be reached via phone at +1-301-8382500 or via email at [email protected]


MarketBeat Community Rating for Supernus Pharmaceuticals (SUPN)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  266 (Vote Outperform)
Underperform Votes:  139 (Vote Underperform)
Total Votes:  405
MarketBeat's community ratings are surveys of what our community members think about Supernus Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Supernus Pharmaceuticals (NASDAQ:SUPN) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.902.892.782.67
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $51.90$50.33$49.89$48.33
Price Target Upside: 32.91% upside8.24% upside30.94% upside17.74% upside

Supernus Pharmaceuticals (NASDAQ:SUPN) Consensus Price Target History

Price Target History for Supernus Pharmaceuticals (NASDAQ:SUPN)

Supernus Pharmaceuticals (NASDAQ:SUPN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/1/2018Berenberg BankInitiated CoverageBuy$66.00HighView Rating Details
1/18/2018B. RileyReiterated RatingBuy -> Buy$54.00HighView Rating Details
12/4/2017Janney Montgomery ScottUpgradeNeutral -> Buy$47.00HighView Rating Details
11/7/2017Stifel NicolausUpgradeHold -> Buy$47.00N/AView Rating Details
11/3/2017SunTrust BanksReiterated RatingBuy$61.00N/AView Rating Details
10/29/2017Piper Jaffray CompaniesSet Price TargetHold$41.00N/AView Rating Details
10/23/2017CowenSet Price TargetBuy$50.00N/AView Rating Details
10/19/2017FBR & CoInitiated CoverageBuy -> Buy$53.00N/AView Rating Details
9/27/2017Cantor FitzgeraldReiterated RatingBuy$49.00LowView Rating Details
9/20/2017Jefferies GroupReiterated RatingBuy$51.00HighView Rating Details
7/18/2016Northland SecuritiesDowngradeOutperform -> Market Perform$24.00N/AView Rating Details
(Data available from 2/24/2016 forward)

Earnings

Supernus Pharmaceuticals (NASDAQ:SUPN) Earnings History and Estimates Chart

Earnings by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Supernus Pharmaceuticals (NASDAQ SUPN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/26/2018$0.27N/AView Earnings Details
11/6/2017Q3 2017$0.27$0.29$78.74 million$80.40 millionViewN/AView Earnings Details
8/2/2017Q2 2017$0.24$0.32$68.54 million$75.83 millionViewListenView Earnings Details
5/9/2017Q1 2017$0.22$0.19$57.91 million$57.58 millionViewListenView Earnings Details
2/28/2017Q4 2016$0.24$0.26$58.87 million$62.37 millionViewN/AView Earnings Details
1/20/2017Q3 2016$0.37$56.23 million$56.81 millionViewN/AView Earnings Details
8/2/2016Q2$0.13$0.18$49.67 million$50.40 millionViewListenView Earnings Details
5/3/2016Q1$0.09$0.08$45.33 million$43.00 millionViewListenView Earnings Details
3/2/2016Q4$0.06$0.14$42.93 million$42.70 millionViewListenView Earnings Details
11/3/2015Q315$0.02$0.08$37.93 million$38.60 millionViewListenView Earnings Details
8/5/2015Q215$0.02$0.03$34.07 million$35.10 millionViewListenView Earnings Details
5/5/2015$0.02$0.02$29.16 million$28.13 millionViewListenView Earnings Details
3/10/2015Q4 2014($0.05)$0.08$26.37 million$30.80 millionViewN/AView Earnings Details
11/11/2014Q314$0.36$0.39$43.10 million$52.50 millionViewN/AView Earnings Details
8/11/2014Q214($0.16)$0.08$19.85 million$29.67 millionViewN/AView Earnings Details
5/12/2014Q114($0.41)($0.38)$9.94 million$9.00 millionViewN/AView Earnings Details
3/12/2014Q413($0.55)($0.65)$7.78 million$10.30 millionViewN/AView Earnings Details
11/12/2013Q313($0.67)($0.78)$2.54 million$1.26 millionViewListenView Earnings Details
8/13/2013Q2 2013($0.65)($0.89)$0.91 million$0.28 millionViewN/AView Earnings Details
5/13/2013Q1 2013($0.63)($0.60)$0.57 million$0.15 millionViewN/AView Earnings Details
3/14/2013Q4 2012($0.73)($0.51)ViewN/AView Earnings Details
11/7/2012Q312($0.62)($0.55)ViewN/AView Earnings Details
8/10/2012Q2 2012($0.48)($0.61)ViewN/AView Earnings Details
6/7/2012Q1 2012($2.06)($6.05)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Supernus Pharmaceuticals (NASDAQ:SUPN) Earnings Estimates

2018 EPS Consensus Estimate: $1.78
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182$0.21$0.27$0.24
Q2 20182$0.42$0.47$0.45
Q3 20182$0.48$0.57$0.53
Q4 20182$0.53$0.60$0.57
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Supernus Pharmaceuticals (NASDAQ:SUPN)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Supernus Pharmaceuticals (NASDAQ SUPN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.70%
Institutional Ownership Percentage: 98.37%
Insider Trades by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)
Institutional Ownership by Quarter for Supernus Pharmaceuticals (NASDAQ:SUPN)

Supernus Pharmaceuticals (NASDAQ SUPN) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/22/2018Padmanabh P BhattVPSell20,000$48.04$960,800.0032,500View SEC Filing  
1/17/2018Padmanabh P BhattVPSell20,000$44.98$899,600.0032,500View SEC Filing  
1/12/2018Victor VaughnVPSell5,750$45.03$258,922.5015,094View SEC Filing  
1/11/2018Gregory S. PatrickCFOSell50,000$43.56$2,178,000.00View SEC Filing  
1/9/2018Victor VaughnVPSell15,000$42.04$630,600.0024,344View SEC Filing  
1/2/2018Victor VaughnVPSell55,000$40.11$2,206,050.00View SEC Filing  
9/8/2017Gregory S. PatrickCFOSell50,000$47.60$2,380,000.00View SEC Filing  
9/8/2017Padmanabh P BhattSVPSell5,000$49.86$249,300.0012,500View SEC Filing  
9/7/2017Stefan K.F. SchwabeInsiderSell95,000$46.59$4,426,050.00View SEC Filing  
8/16/2017Padmanabh P BhattVPSell3,709$45.23$167,758.0717,500View SEC Filing  
7/12/2017Padmanabh P BhattVPSell3,735$44.90$167,701.5021,209View SEC Filing  
6/23/2017Padmanabh P BhattVPSell2,556$44.90$114,764.4024,944View SEC Filing  
6/2/2017Padmanabh P BhattVPSell10,000$39.86$398,600.0027,500View SEC Filing  
5/26/2017Padmanabh P BhattVPSell2,500$35.90$89,750.0037,500View SEC Filing  
5/25/2017Padmanabh P BhattVPSell5,500$34.90$191,950.0043,887View SEC Filing  
4/24/2017Gregory S PatrickCFOSell54,000$32.37$1,747,980.0054,221View SEC Filing  
4/24/2017Padmanabh P BhattVPSell11,806$32.59$384,757.5445,500View SEC Filing  
9/16/2016Gregory S PatrickCFOSell2,000$25.00$50,000.003,616View SEC Filing  
7/14/2016Gregory S. PatrickCFOSell3,395$22.00$74,690.00View SEC Filing  
4/11/2016Padmanabh P BhattVPSell30,762$16.49$507,265.3857,306View SEC Filing  
12/9/2015Padmanabh P. BhattVPSell14,238$14.90$212,146.2088,068View SEC Filing  
12/8/2015M James BarrettDirectorSell212,970$14.56$3,100,843.20115,355View SEC Filing  
11/25/2015M James BarrettDirectorSell16,179$16.35$264,526.6573,929View SEC Filing  
11/18/2015M James BarrettDirectorSell93,000$16.61$1,544,730.0073,929View SEC Filing  
11/16/2015M James BarrettDirectorSell119,650$16.24$1,943,116.0073,929View SEC Filing  
11/4/2015Padmanabh P BhattVPSell5,000$19.90$99,500.00102,306View SEC Filing  
7/16/2015Gregory S PatrickCFOSell6,217$20.00$124,340.00View SEC Filing  
7/13/2015Stefan K.F. SchwabeEVPSell1,950$19.23$37,498.50View SEC Filing  
6/17/2015M James BarrettDirectorSell111,881$16.39$1,833,729.59View SEC Filing  
6/17/2015Scott D SandellMajor ShareholderSell136,597$16.50$2,253,850.50View SEC Filing  
6/16/2015M James BarrettDirectorSell55,105$16.85$928,519.25View SEC Filing  
6/16/2015Scott D SandellMajor ShareholderSell95,437$16.92$1,614,794.04View SEC Filing  
6/12/2015Stefan K.F. SchwabeEVPSell2,051$18.27$37,471.77View SEC Filing  
6/11/2015Stefan K.F. SchwabeEVPSell3,631$16.39$59,512.09View SEC Filing  
3/24/2015Jones W BryanVPSell1,900$12.00$22,800.00View SEC Filing  
8/19/2013Padmanabh BhattVPSell2,285$8.21$18,759.8551,806View SEC Filing  
3/22/2013Michael BighamDirectorBuy35,000$5.41$189,350.00View SEC Filing  
3/21/2013John M SiebertDirectorBuy3,000$5.50$16,500.00View SEC Filing  
3/15/2013Jack A KhattarCEOBuy10,000$6.15$61,500.00View SEC Filing  
3/14/2013Gregory S PatrickCFOBuy5,000$6.95$34,750.00View SEC Filing  
12/4/2012John M SiebertDirectorBuy7,000$8.14$56,980.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Supernus Pharmaceuticals (NASDAQ SUPN) News Headlines

Source:
DateHeadline
Supernus Pharmaceuticals Inc (SUPN) Expected to Announce Quarterly Sales of $88.02 MillionSupernus Pharmaceuticals Inc (SUPN) Expected to Announce Quarterly Sales of $88.02 Million
www.americanbankingnews.com - February 23 at 2:38 AM
Quotidian Technical Highlights on Selected Generic Drugs Stocks -- Allergan, Catalyst Pharma, Flexion Therapeutics ... - PR Newswire (press release)Quotidian Technical Highlights on Selected Generic Drugs Stocks -- Allergan, Catalyst Pharma, Flexion Therapeutics ... - PR Newswire (press release)
www.prnewswire.com - February 22 at 8:20 AM
 Brokerages Expect Supernus Pharmaceuticals Inc (SUPN) to Announce $0.26 Earnings Per Share Brokerages Expect Supernus Pharmaceuticals Inc (SUPN) to Announce $0.26 Earnings Per Share
www.americanbankingnews.com - February 21 at 7:14 PM
Supernus Pharmaceuticals (SUPN) Set to Announce Earnings on MondaySupernus Pharmaceuticals (SUPN) Set to Announce Earnings on Monday
www.americanbankingnews.com - February 19 at 4:44 AM
Supernus Pharmaceuticals Inc (SUPN) Receives Average Recommendation of "Buy" from BrokeragesSupernus Pharmaceuticals Inc (SUPN) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - February 13 at 1:44 PM
Supernus to Host Fourth Quarter and Full Year 2017 Earnings Conference CallSupernus to Host Fourth Quarter and Full Year 2017 Earnings Conference Call
finance.yahoo.com - February 13 at 9:49 AM
 Brokerages Expect Supernus Pharmaceuticals Inc (SUPN) Will Post Quarterly Sales of $88.02 Million Brokerages Expect Supernus Pharmaceuticals Inc (SUPN) Will Post Quarterly Sales of $88.02 Million
www.americanbankingnews.com - February 6 at 2:26 AM
$0.26 Earnings Per Share Expected for Supernus Pharmaceuticals Inc (SUPN) This Quarter$0.26 Earnings Per Share Expected for Supernus Pharmaceuticals Inc (SUPN) This Quarter
www.americanbankingnews.com - February 4 at 7:08 PM
Supernus Pharmaceuticals (SUPN) Cut to Hold at BidaskClubSupernus Pharmaceuticals (SUPN) Cut to Hold at BidaskClub
www.americanbankingnews.com - February 1 at 6:52 AM
Supernus Pharmaceuticals (SUPN) Downgraded to Buy at BidaskClubSupernus Pharmaceuticals (SUPN) Downgraded to Buy at BidaskClub
www.americanbankingnews.com - January 27 at 12:18 AM
Supernus Pharmaceuticals Inc (SUPN) VP Sells $960,800.00 in StockSupernus Pharmaceuticals Inc (SUPN) VP Sells $960,800.00 in Stock
www.americanbankingnews.com - January 22 at 9:22 PM
Today’s Research Reports on Trending Tickers: Supernus Pharmaceuticals and Synergy PharmaceuticalsToday’s Research Reports on Trending Tickers: Supernus Pharmaceuticals and Synergy Pharmaceuticals
finance.yahoo.com - January 22 at 3:52 PM
Equities Analysts Issue Forecasts for Supernus Pharmaceuticals Incs FY2022 Earnings (SUPN)Equities Analysts Issue Forecasts for Supernus Pharmaceuticals Inc's FY2022 Earnings (SUPN)
www.americanbankingnews.com - January 22 at 3:22 PM
Supernus Pharmaceuticals (SUPN) "Buy" Rating Reaffirmed at B. RileySupernus Pharmaceuticals' (SUPN) "Buy" Rating Reaffirmed at B. Riley
www.americanbankingnews.com - January 21 at 11:38 PM
Supernus Pharmaceuticals Inc (SUPN) Expected to Post Quarterly Sales of $88.02 MillionSupernus Pharmaceuticals Inc (SUPN) Expected to Post Quarterly Sales of $88.02 Million
www.americanbankingnews.com - January 20 at 4:56 AM
Supernus Pharmaceuticals Target of Unusually Large Options Trading (SUPN)Supernus Pharmaceuticals Target of Unusually Large Options Trading (SUPN)
www.americanbankingnews.com - January 20 at 3:10 AM
Supernus Pharmaceuticals Inc (SUPN) Given Consensus Rating of "Buy" by BrokeragesSupernus Pharmaceuticals Inc (SUPN) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 19 at 3:40 PM
$0.26 EPS Expected for Supernus Pharmaceuticals Inc (SUPN) This Quarter$0.26 EPS Expected for Supernus Pharmaceuticals Inc (SUPN) This Quarter
www.americanbankingnews.com - January 18 at 7:36 PM
Supernus Pharmaceuticals Stock Is an Institutional FavoriteSupernus Pharmaceuticals Stock Is an Institutional Favorite
finance.yahoo.com - January 18 at 10:41 AM
Supernus Pharmaceuticals Inc (SUPN) VP Padmanabh P. Bhatt Sells 20,000 SharesSupernus Pharmaceuticals Inc (SUPN) VP Padmanabh P. Bhatt Sells 20,000 Shares
www.americanbankingnews.com - January 17 at 9:32 PM
Insider Selling: Supernus Pharmaceuticals Inc (SUPN) VP Sells 5,750 Shares of StockInsider Selling: Supernus Pharmaceuticals Inc (SUPN) VP Sells 5,750 Shares of Stock
www.americanbankingnews.com - January 16 at 7:08 PM
Supernus Pharmaceuticals (SUPN) Raised to "Strong-Buy" at BidaskClubSupernus Pharmaceuticals (SUPN) Raised to "Strong-Buy" at BidaskClub
www.americanbankingnews.com - January 14 at 9:38 PM
Supernus Pharma (SUPN) Announces Passing of Board Member William Nuerge on January 10, 2018 - StreetInsider.comSupernus Pharma (SUPN) Announces Passing of Board Member William Nuerge on January 10, 2018 - StreetInsider.com
www.streetinsider.com - January 13 at 3:27 PM
Supernus Pharmaceuticals (SUPN) Downgraded by Zacks Investment Research to "Hold"Supernus Pharmaceuticals (SUPN) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - January 13 at 12:42 AM
Insider Selling: Supernus Pharmaceuticals Inc (SUPN) CFO Sells 50,000 Shares of StockInsider Selling: Supernus Pharmaceuticals Inc (SUPN) CFO Sells 50,000 Shares of Stock
www.americanbankingnews.com - January 12 at 6:26 PM
Supernus Mourns the Loss of Board Member William Nuerge - GlobeNewswire (press release)Supernus Mourns the Loss of Board Member William Nuerge - GlobeNewswire (press release)
globenewswire.com - January 12 at 3:27 PM
Supernus Mourns the Loss of Board Member William NuergeSupernus Mourns the Loss of Board Member William Nuerge
finance.yahoo.com - January 12 at 3:27 PM
Supernus Pharmaceuticals Inc (SUPN) Forecasted to Post FY2018 Earnings of $1.82 Per ShareSupernus Pharmaceuticals Inc (SUPN) Forecasted to Post FY2018 Earnings of $1.82 Per Share
www.americanbankingnews.com - January 11 at 3:36 PM
Supernus Pharmaceuticals (SUPN) Upgraded to Buy at Zacks Investment ResearchSupernus Pharmaceuticals (SUPN) Upgraded to Buy at Zacks Investment Research
www.americanbankingnews.com - January 10 at 12:04 PM
Supernus Pharmaceuticals Earns Relative Strength Rating Upgrade; Hits Key ThresholdSupernus Pharmaceuticals Earns Relative Strength Rating Upgrade; Hits Key Threshold
finance.yahoo.com - January 10 at 10:51 AM
Insider Selling: Supernus Pharmaceuticals Inc (SUPN) VP Sells 15,000 Shares of StockInsider Selling: Supernus Pharmaceuticals Inc (SUPN) VP Sells 15,000 Shares of Stock
www.americanbankingnews.com - January 9 at 9:38 PM
Supernus Pharmaceuticals Inc (SUPN) VP Sells $2,206,050.00 in StockSupernus Pharmaceuticals Inc (SUPN) VP Sells $2,206,050.00 in Stock
www.americanbankingnews.com - January 4 at 7:02 PM
Supernus to Present at the 2018 JP Morgan Healthcare Conference - GlobeNewswire (press release)Supernus to Present at the 2018 JP Morgan Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - January 2 at 8:42 PM
Supernus to Present at the 2018 J.P. Morgan Healthcare ConferenceSupernus to Present at the 2018 J.P. Morgan Healthcare Conference
finance.yahoo.com - January 2 at 8:42 PM
Q1 2018 Earnings Forecast for Supernus Pharmaceuticals Inc Issued By B. Riley (SUPN)Q1 2018 Earnings Forecast for Supernus Pharmaceuticals Inc Issued By B. Riley (SUPN)
www.americanbankingnews.com - January 1 at 3:00 AM
Q3 2018 EPS Estimates for Supernus Pharmaceuticals Inc (SUPN) Raised by AnalystQ3 2018 EPS Estimates for Supernus Pharmaceuticals Inc (SUPN) Raised by Analyst
www.americanbankingnews.com - December 29 at 1:24 PM
Supernus Pharmaceuticals Shows Rising Price Performance With Jump To 81 RS RatingSupernus Pharmaceuticals Shows Rising Price Performance With Jump To 81 RS Rating
finance.yahoo.com - December 29 at 10:58 AM
Supernus Pharmaceuticals (SUPN) Price Target Raised to $54.00 at B. RileySupernus Pharmaceuticals (SUPN) Price Target Raised to $54.00 at B. Riley
www.americanbankingnews.com - December 28 at 8:18 AM
ETFs with exposure to Supernus Pharmaceuticals, Inc. : December 26, 2017ETFs with exposure to Supernus Pharmaceuticals, Inc. : December 26, 2017
finance.yahoo.com - December 26 at 12:49 PM
Supernus Pharmaceuticals, Inc. :SUPN-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017Supernus Pharmaceuticals, Inc. :SUPN-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
finance.yahoo.com - December 25 at 4:09 PM
Supernus Pharmaceuticals Inc (SUPN) Given Average Rating of "Buy" by AnalystsSupernus Pharmaceuticals Inc (SUPN) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - December 25 at 1:52 PM
Zacks: Brokerages Expect Supernus Pharmaceuticals Inc (SUPN) Will Post Quarterly Sales of $88.02 MillionZacks: Brokerages Expect Supernus Pharmaceuticals Inc (SUPN) Will Post Quarterly Sales of $88.02 Million
www.americanbankingnews.com - December 18 at 6:00 PM
Supernus Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SUPN) : December 15, 2017Supernus Pharmaceuticals, Inc. – Value Analysis (NASDAQ:SUPN) : December 15, 2017
finance.yahoo.com - December 15 at 3:32 PM
Supernus Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SUPN-US : December 14, 2017Supernus Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : SUPN-US : December 14, 2017
finance.yahoo.com - December 14 at 9:41 AM
Stocks Showing Improved Relative Strength: Supernus PharmaceuticalsStocks Showing Improved Relative Strength: Supernus Pharmaceuticals
finance.yahoo.com - December 13 at 3:29 PM
Stocks Generating Improved Relative Strength: Supernus PharmaceuticalsStocks Generating Improved Relative Strength: Supernus Pharmaceuticals
finance.yahoo.com - December 11 at 3:28 PM
Best-In-Class NasdaqGM Growth StocksBest-In-Class NasdaqGM Growth Stocks
finance.yahoo.com - December 10 at 3:31 PM
Supernus Pharmaceuticals (SUPN) Raised to Buy at Janney Montgomery ScottSupernus Pharmaceuticals (SUPN) Raised to Buy at Janney Montgomery Scott
www.americanbankingnews.com - December 4 at 8:22 PM
Benzingas Top Upgrades, Downgrades For December 4, 2017 - BenzingaBenzinga's Top Upgrades, Downgrades For December 4, 2017 - Benzinga
www.benzinga.com - December 4 at 9:44 AM
Supernus Pharmaceuticals (SUPN) Downgraded to "Hold" at ValuEngineSupernus Pharmaceuticals (SUPN) Downgraded to "Hold" at ValuEngine
www.americanbankingnews.com - December 2 at 4:02 PM

SEC Filings

Supernus Pharmaceuticals (NASDAQ:SUPN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Supernus Pharmaceuticals (NASDAQ:SUPN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Supernus Pharmaceuticals (NASDAQ SUPN) Stock Chart for Saturday, February, 24, 2018

Loading chart…

This page was last updated on 2/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.